QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ALLO

QT66Allogene Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
2.00
+0.04+2.04%
OverviewShort InterestFilings
ALLOQT66Allogene Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
2.00+2.04%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand-
Perf Week6.38%
Market Cap477.98MForward P/E-EPS next Y-0.75Insider Trans-Shs Float-Perf Month5.82%
Enterprise Value528.73MPEG-EPS next Q-0.16Inst Own-Short Float-Perf Quarter-9.91%
Income-176328303.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y29.87%
Sales-P/B1.69EPS next Y-6.71%ROA-43.88%Short Interest-Perf YTD45.99%
Book/sh-P/C-EPS next 5Y-ROE-56.45%52W High4.46 -55.16%Perf Year53.85%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-50.58%52W Low0.98 103.21%Perf 3Y-
Dividend Est.-EV/EBITDA-3.30Sales past 3/5Y-Gross Margin0.00%Volatility5.06% 4.56%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM41.67%Oper. Margin0.00%ATR (14)0.14Perf 10Y-
Dividend Ex-Date-Quick Ratio9.65Sales Y/Y TTM-Profit Margin0.00%RSI (14)48.82Recom2.67
Dividend Gr. 3/5Y-Current Ratio9.65EPS Q/Q35.71%SMA200.25%Beta2.53Target Price6.43
Payout0.00%Debt/Eq0.29Sales Q/Q-SMA50-7.83%Rel Volume2.03Prev Close1.96
Employees226LT Debt/Eq0.26EarningsAug 12SMA20013.78%Avg Volume11.62MPrice2.00
IPO DateOct 11, 2018Option/ShortNo / YesEPS/Sales Surpr.5.26% -Net Debt/EBITDA-0.32Volume23,541,059Change2.04%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-16-26UpgradeJP MorganUnderweight → Neutral
Apr-14-26ReiteratedRobert W. Baird$7.00 → $9.00
Apr-14-26ReiteratedBernsteinMarket Perform$3.85
Jan-09-26UpgradeCitizensMarket Perform → Market Outperform
Oct-10-25DowngradeJP MorganNeutral → Underweight
Aug-04-25DowngradeJP MorganOverweight → Neutral
Mar-14-25UpgradeCitizens Capital MarketsMarket Perform → Market Outperform
May-16-24ReiteratedH.C. Wainwright$9.00
May-14-24ReiteratedB.Riley Financial$7.00
Jan-05-24DowngradeJMP SecuritiesMarket Outperform → Market Perform
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A1200
Gross Profit-1200
Selling, General and Administrative Excl. Other576572
Research and Development150192243
Other Operating Expense-121613
Operating Income-207-273-328
Interest Expense100
Unusual Expense
———
Non-Operating Income (Expense)-17-160
Net Income Before Taxes-191-257-327
Income Taxes
000
Consolidated Net Income-191-258-327
Net Income From Continuing Operations-191-258-327
Net Income-191-258-327
EPS (Recurring)-0.87-1.32-2.09
EPS (Basic, Before Extraordinaries)-0.87-1.32-2.09
EPS (Diluted)-0.87-1.32-2.09
EBITDA-177-243-313
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin———
Operating Margin———
Net Margin———
Shares Outstanding221195157
Market Capitalization303——
Operating Lease Expense
———
Insider Trading Volume
$2.23$2.06$1.90$1.74$1.57● Close Price0.00K84.36K168.72K253.08K337.45KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Yoshiyama AnnieSVP, FinanceApr 21 '26Sale2.319,58622,144124,517Apr 23 12:00 AM
Beneski Benjamin MachinasSVP, Chief Technical OfficerMar 31 '26Sale2.502,8677,168195,338Apr 02 12:00 AM
Beneski Benjamin MachinasSVP, Chief Technical OfficerMar 16 '26Sale2.474,83511,942198,205Mar 18 12:00 AM
Chang David DPresident and CEOMar 16 '26Sale2.4747,763117,9755,150,599Mar 18 12:00 AM
Beneski Benjamin MachinasSVP, Chief Technical OfficerMar 02 '26Sale2.607,13218,543203,040Mar 04 12:00 AM
Parker Geoffrey M.CHIEF FINANCIAL OFFICERFeb 02 '26Sale1.7624,00142,2421,252,795Feb 04 12:00 AM
Douglas Earl MartinSVP, General CounselFeb 02 '26Sale1.7622,90040,304564,948Feb 04 12:00 AM
Yoshiyama AnnieSVP, FinanceFeb 02 '26Sale1.724,1677,167130,322Feb 04 12:00 AM
Roberts ZacharyEVP of R&DFeb 02 '26Sale1.7735,70063,189581,166Feb 04 12:00 AM
Beneski Benjamin MachinasSVP, Chief Technical OfficerFeb 02 '26Sale1.737,54913,060210,172Feb 04 12:00 AM
Chang David DPresident and CEOFeb 02 '26Sale1.8095,269171,4845,185,862Feb 04 12:00 AM
Roberts ZacharyEVP of R&DJan 21 '26Sale1.5626,26940,980616,866Jan 23 12:00 AM
Kazam Joshua ADirectorDec 18 '25Option Exercise0.0095,4000350,763Dec 22 12:00 AM
Beneski Benjamin MachinasSVP, Chief Technical OfficerNov 17 '25Sale1.22786959217,721Nov 19 12:00 AM
Parker Geoffrey M.CHIEF FINANCIAL OFFICEROct 21 '25Sale1.2636,74446,1691,276,796Oct 23 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR